Wall Street equity research analysts tracking Spruce Biosciences generally assign mixed or cautious consensus ratings—such as Hold or moderate Speculative Buy perspectives—reflecting the high-risk, high-reward nature of clinical-stage biotechnology equities. Target prices and recommendations fluctuate dynamically based on upcoming clinical trial data readouts and regulatory updates regarding their core drug candidates.